MacroGenics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company�s product candidates leverage its fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three technology platforms: its Dual-Affinity Re-Targeting (DART) platform enables the Company to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; its Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and its Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy. As of December 31, 2012, the Company had two oncology product candidates in clinical development.